To Mysscat, Erthang, LT, Bocxman, and others:
Do any of you work in R&D, or in technology development?
I do, and I can tell you from experience that it's extremely difficult to take a new technology from the lab to being a commercial success. Dozens of problems have to be overcome, and if only one of them cannot be overcome, the new technology will not become a commercial success.
Although RECAF works for Biocurex, there's no guarantee that it will work for Abbott in its Architect system. The fact that it's been 18 months since the Abbott licensing deal was first announced, and nothing further about this deal or the progress that Abbott has made, has been announced, is an indication that integrating RECAF into the Architect system may be more difficult than some might have expected.
From Biocurex's last press release: ...it is important to realize that the RECAF technology is very complex. Development of the technology is very tricky... This could be a back-handed way of indicating that Abbott, and/or BOCX has encountered some problems with RECAF.
Of course, if Abbott is successful in integrating RECAF into its Architect system, the upside for BOCX, and for us, its investors, is quite large - that's why I own shares in this company. However, based on my ~ 25 years experience in technology development and in investing, RECAF and BOCX are still somewhat of a long shot. It would be foolish to invest more than a small fraction of your portfolio in this company.
I hope that you haven't fallen in love with this, or any stock, and refrain from attacking those who have some doubts or negative sentiments about the company. I sincerely doubt that there are any paid bashers on this board - BOCX is simply to small for it to be worth their while. Those who express negative sentiments are most likely voicing legitimate concerns, or simply venting their frustration at the stock's performance.
Hopefully, we can have a civil exchange of views, and become more knowledgable and successful investors in the process.
A1
